Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27119
IPSCIO Record ID: 4947
IPSCIO Record ID: 203490
For the Screening license, Licensor grants a non-exclusive license under the Licensors Technology and Licensors interest in any Joint Know-How in the United States solely as necessary to carry out the Research hereunder during the Research Term. Such license shall not be sublicensable.
For the Development and Commercialization license, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to generate and screen Licensees Mabs; and create Derivatives of Selected Mabs and Licensee Mabs, and develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products for use in the Commercial Field in the Territory.
And, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to use the Selected Targets to generate and screen Licensee Mabs, and develop Licensed Mabs in the Commercial Field in the Territory during the Term.
Licensor Technology shall mean any Know-How that is and all Patents claiming inventions that are useful or necessary to generate and to screen Mabs binding to a Molecular Target, including without limitation methods of immunization, methods for maintaining and handling cell lines expressing Mabs, production and freezing media, and antibody screening facilitation tools including without limitation CellArrayâ„¢, controlled by Licensor as of the effective date and during the term, and disclosed by Licensor to Licensee during the Term.
Joint Know-How shall mean any Know-How jointly invented by both Parties in the conduct of the Research, invented by Licensor in the conduct of the Research as a direct result of its use of Licensees Technology, or, invented by Licensee in the conduct of the Research as a direct result of its use of Licensors Technology.
Licensed Product shall mean any pharmaceutical product containing a Licensed Mab.
Cytotoxic Compound shall mean any Cytotoxic compound and all variants, fragments or derivatives thereof, whether produced by a botanical source, natural fermentation or chemical synthesis, which is, in any case, controlled by Licensee.
Naked Mab Licensed Product shall mean any Licensed Product that is not a Cytotoxin-Coupled Licensed Product.
Antigen shall mean any protein, peptide or carbohydrate or other composition, and/or any fragment, peptide and/or epitope thereof which causes an immune response that produces antibodies.
The Commercial Field shall mean therapeutic products employing Mabs, alone or in conjunction with other ingredients, to treat cancer in humans.
IPSCIO Record ID: 26237
Patent Antigen binding proteins that bind PD-L1
IPSCIO Record ID: 256217
The Licensor grants a co-exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use. For purposes of this Agreement co-exclusive shall mean that at any time only the Licensee and its Affiliates, on the one hand, and one other Licensee and its Affiliates, on the other hand, shall at any time have a license or other right from the Licensor under the Licensed Patent Rights in the Licensed Territory in the Licensed Fields of Use.
– Development and manufacture of synovial sarcoma breakpoint X-2 (SSX-2) T cell receptor (TCR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of head and neck cancer, hepatocellular carcinoma, melanoma, prostate cancer, and sarcoma.
– Development and manufacture of epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of brain cancer, head and neck cancer, and melanoma.
– Development and manufacture of synovial sarcoma breakpoint X-2 (SSX-2) T cell receptor (TCR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of breast cancer, ovarian cancer, and colorectal cancer.
– Development and manufacture of epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR)-based autologous peripheral blood T cell therapy products as set forth in the Licensed Patent Rights for the treatment of breast cancer, ovarian cancer, and colorectal cancer.
For purposes of the Agreement, autologous peripheral blood T cell therapy products shall mean T cell or precursor products and compositions derived from blood, bone marrow, lymph nodes and thymus and, for the avoidance of doubt, shall exclude tumor-infiltrating lymphocytes (TILs).
IPSCIO Record ID: 368653
Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.
Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.
These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.
This agreements focus is cancer immunotherapy.
IPSCIO Record ID: 27133
– U.S. Patent 5,614,191 issued March 25, 1997
– USSN 08/821,840 (div of 08/404,685) filed March 21, 1997
Patent(s) or Patent Application(s) that are Background Patent Rights
– U.S. Patent 4,892,827 issued January 9, 1990
The Company entered into an exclusive worldwide licensing agreement with the National Institutes of Health and the FDA to develop and commercialize an IL-13 chimeric protein therapy.
The IL-13 chimeric protein is the fusion of the receptor-binding ligand IL-13 with a derivative of Pseudomonas exotoxin (PE38QQR). Research has demonstrated that some solid tumors express high numbers of IL-13 receptors on their cell surfaces. These receptor sites become a specific target for the IL-13 chimeric protein for inducing cytotoxicity at nanogram concentrations. IL-13 Chimeric Protein Exotoxin is a genetically engineered compound incorporating a highly toxic material that destroys cells once linked to the target receptor on its surface. Pre-clinical trials ongoing, initiate Phase I in the 2nd Quarter, 1999.
Cancer Indication Renal Cell, Brain, Kaposi's Sarcoma, Breast.
IPSCIO Record ID: 29400
OvaRexÂ® MAb is intended for the treatment of ovarian cancer.
IPSCIO Record ID: 229530
IPSCIO Record ID: 275366
The product, Ofatumumab, is being commercialized by Licensee.
Ofatumumab is a human IgG1k mAb that targets an epitope on the CD20 molecule, which is found on the surface of B-cells, the type of cell which is believed to trigger the inflammatory process that leads to multiple sclerosis (MS).